Corbus Pharmaceuticals' (CRBP) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Corbus Pharmaceuticals received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook for the stock.
• The company has shown significant volatility, trading between a 12-month low of $4.64 and a high of $20.77, with current shares at $13.42.
• Despite being rated as a "Moderate Buy" on average by analysts, there is a wide range of target prices, with HC Wainwright setting it as high as $40.00.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other analysts also recently issued reports about the stock. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday, September 17th. Oppenheimer lowered their price objective on shares of Corbus Pharmaceuticals from $56.00 to $53.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 6th. B. Riley raised shares of Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 price objective on the stock in a research note on Wednesday, July 30th. Finally, Lifesci Capital raised shares of Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Saturday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $45.43.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP stock traded down $1.19 during midday trading on Wednesday, reaching $13.42. 191,493 shares of the company were exchanged, compared to its average volume of 177,758. Corbus Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $20.77. The company has a market cap of $164.53 million, a P/E ratio of -2.82 and a beta of 2.84. The company's 50 day moving average price is $10.49 and its two-hundred day moving average price is $8.46.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping analysts' consensus estimates of ($1.55) by $0.11. As a group, sell-side analysts predict that Corbus Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRBP. Corton Capital Inc. purchased a new position in Corbus Pharmaceuticals during the second quarter valued at approximately $86,000. Marshall Wace LLP purchased a new position in Corbus Pharmaceuticals during the second quarter valued at approximately $137,000. Baker Avenue Asset Management LP purchased a new position in Corbus Pharmaceuticals during the second quarter valued at approximately $138,000. Y Intercept Hong Kong Ltd purchased a new position in Corbus Pharmaceuticals during the second quarter valued at approximately $141,000. Finally, Stonepine Capital Management LLC purchased a new position in Corbus Pharmaceuticals during the first quarter valued at approximately $186,000. 64.64% of the stock is owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.